interviews: Sophie Renhuldt
An agreement has been reached between the Region and bio-pharmaceutical giant AstraZeneca, poised to revolutionize Friuli Venezia Giulia’s life sciences sector. Governor Fedriga hailed the deal as a pivotal step forward, emphasizing, “The presence of industry leaders ensures the cultivation of expertise and strategic healthcare investment.”
AstraZeneca’s President, Claudio Longo, echoed this sentiment, highlighting the agreement’s significance. He noted that it marks the beginning of groundbreaking clinical studies and digital health initiatives, promising to propel the region’s research and innovation ecosystem to new heights.
This collaboration sets the stage for a dynamic partnership, fostering knowledge exchange and collaborative networks between the company and regional health entities. Health Assessor Riccardi stressed the protocol’s pivotal role, while Assessor Rosolen emphasized the region’s substantial investments, totaling €28.5 million. These funds are aimed at fortifying the life sciences landscape, supporting startups, and driving research and innovation projects throughout the region.
